Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures

John Christopher G. Gallagher, Harry K. Genant, Gerald G. Crans, Socorro Juan Vargas, John H. Krege

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

The relationship between prior fractures and risk of new fractures was evaluated in 931 postmenopausal women with prevalent vertebral fractures randomized to daily placebo or teriparatide (20 μg) in the Fracture Prevention Trial. The median observation time was 21 months. Among placebo patients with one, two, or three or more prevalent vertebral fractures, 7%, 16%, and 23%, respectively, developed vertebral fractures (by Cochran-Armitage trend test, P <0.001), and 3%, 9%, and 17% developed moderate or severe vertebral fractures (P <0.001). Among placebo patients with mild, moderate, or severe prevalent vertebral fractures, 10%, 13%, and 28%, respectively, developed vertebral fractures (P <0.001), and 4%, 8%, and 23% developed moderate or severe vertebral fractures (P <0.001). Among placebo patients with zero, one, or two or more prior nonvertebral fragility fractures, 4%, 8%, and 18%, respectively, developed nonvertebral fragility fractures (P <0.001). In the teriparatide-treated group, there was no significant increase in vertebral or nonvertebral fracture risk in these subgroups. In summary, the number and severity of prevalent vertebral fractures independently predicted the risk for new vertebral fractures, and the number of prior nonvertebral fractures predicted the risk for new nonvertebral fractures in placebo patients. However, in teriparatide-treated patients, the increased fracture risk associated with prior number and severity of fracture was not observed.

Original languageEnglish
Pages (from-to)1583-1587
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume90
Issue number3
DOIs
StatePublished - Mar 2005

Fingerprint

Teriparatide
Osteoporotic Fractures
Placebos
Observation

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. / Gallagher, John Christopher G.; Genant, Harry K.; Crans, Gerald G.; Vargas, Socorro Juan; Krege, John H.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 90, No. 3, 03.2005, p. 1583-1587.

Research output: Contribution to journalArticle

Gallagher, John Christopher G. ; Genant, Harry K. ; Crans, Gerald G. ; Vargas, Socorro Juan ; Krege, John H. / Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. In: Journal of Clinical Endocrinology and Metabolism. 2005 ; Vol. 90, No. 3. pp. 1583-1587.
@article{0a7fd8095d7a45c5990afaf33417c99b,
title = "Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures",
abstract = "The relationship between prior fractures and risk of new fractures was evaluated in 931 postmenopausal women with prevalent vertebral fractures randomized to daily placebo or teriparatide (20 μg) in the Fracture Prevention Trial. The median observation time was 21 months. Among placebo patients with one, two, or three or more prevalent vertebral fractures, 7{\%}, 16{\%}, and 23{\%}, respectively, developed vertebral fractures (by Cochran-Armitage trend test, P <0.001), and 3{\%}, 9{\%}, and 17{\%} developed moderate or severe vertebral fractures (P <0.001). Among placebo patients with mild, moderate, or severe prevalent vertebral fractures, 10{\%}, 13{\%}, and 28{\%}, respectively, developed vertebral fractures (P <0.001), and 4{\%}, 8{\%}, and 23{\%} developed moderate or severe vertebral fractures (P <0.001). Among placebo patients with zero, one, or two or more prior nonvertebral fragility fractures, 4{\%}, 8{\%}, and 18{\%}, respectively, developed nonvertebral fragility fractures (P <0.001). In the teriparatide-treated group, there was no significant increase in vertebral or nonvertebral fracture risk in these subgroups. In summary, the number and severity of prevalent vertebral fractures independently predicted the risk for new vertebral fractures, and the number of prior nonvertebral fractures predicted the risk for new nonvertebral fractures in placebo patients. However, in teriparatide-treated patients, the increased fracture risk associated with prior number and severity of fracture was not observed.",
author = "Gallagher, {John Christopher G.} and Genant, {Harry K.} and Crans, {Gerald G.} and Vargas, {Socorro Juan} and Krege, {John H.}",
year = "2005",
month = "3",
doi = "10.1210/jc.2004-0826",
language = "English",
volume = "90",
pages = "1583--1587",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures

AU - Gallagher, John Christopher G.

AU - Genant, Harry K.

AU - Crans, Gerald G.

AU - Vargas, Socorro Juan

AU - Krege, John H.

PY - 2005/3

Y1 - 2005/3

N2 - The relationship between prior fractures and risk of new fractures was evaluated in 931 postmenopausal women with prevalent vertebral fractures randomized to daily placebo or teriparatide (20 μg) in the Fracture Prevention Trial. The median observation time was 21 months. Among placebo patients with one, two, or three or more prevalent vertebral fractures, 7%, 16%, and 23%, respectively, developed vertebral fractures (by Cochran-Armitage trend test, P <0.001), and 3%, 9%, and 17% developed moderate or severe vertebral fractures (P <0.001). Among placebo patients with mild, moderate, or severe prevalent vertebral fractures, 10%, 13%, and 28%, respectively, developed vertebral fractures (P <0.001), and 4%, 8%, and 23% developed moderate or severe vertebral fractures (P <0.001). Among placebo patients with zero, one, or two or more prior nonvertebral fragility fractures, 4%, 8%, and 18%, respectively, developed nonvertebral fragility fractures (P <0.001). In the teriparatide-treated group, there was no significant increase in vertebral or nonvertebral fracture risk in these subgroups. In summary, the number and severity of prevalent vertebral fractures independently predicted the risk for new vertebral fractures, and the number of prior nonvertebral fractures predicted the risk for new nonvertebral fractures in placebo patients. However, in teriparatide-treated patients, the increased fracture risk associated with prior number and severity of fracture was not observed.

AB - The relationship between prior fractures and risk of new fractures was evaluated in 931 postmenopausal women with prevalent vertebral fractures randomized to daily placebo or teriparatide (20 μg) in the Fracture Prevention Trial. The median observation time was 21 months. Among placebo patients with one, two, or three or more prevalent vertebral fractures, 7%, 16%, and 23%, respectively, developed vertebral fractures (by Cochran-Armitage trend test, P <0.001), and 3%, 9%, and 17% developed moderate or severe vertebral fractures (P <0.001). Among placebo patients with mild, moderate, or severe prevalent vertebral fractures, 10%, 13%, and 28%, respectively, developed vertebral fractures (P <0.001), and 4%, 8%, and 23% developed moderate or severe vertebral fractures (P <0.001). Among placebo patients with zero, one, or two or more prior nonvertebral fragility fractures, 4%, 8%, and 18%, respectively, developed nonvertebral fragility fractures (P <0.001). In the teriparatide-treated group, there was no significant increase in vertebral or nonvertebral fracture risk in these subgroups. In summary, the number and severity of prevalent vertebral fractures independently predicted the risk for new vertebral fractures, and the number of prior nonvertebral fractures predicted the risk for new nonvertebral fractures in placebo patients. However, in teriparatide-treated patients, the increased fracture risk associated with prior number and severity of fracture was not observed.

UR - http://www.scopus.com/inward/record.url?scp=15944389876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15944389876&partnerID=8YFLogxK

U2 - 10.1210/jc.2004-0826

DO - 10.1210/jc.2004-0826

M3 - Article

VL - 90

SP - 1583

EP - 1587

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -